Disease · HP_0002619

Varicose veins

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Varicose veins. Diseases, record HP_0002619. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002619

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Varicose veins; Open Targets
Open Targets ID: HP_0002619; Open Targets
Disease Ontology: DOID:799; Disease Ontology
Highest stage of its drugs: Approval, for 10 of its 18 drugs, from ATC and TTD; Open Targets

Drugs18

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
POLIDOCANOL	CHEMBL6067961	Small molecule	Approval	ATC and TTD	12	10	10	Drugs and targets
SODIUM TETRADECYL SULFATE	CHEMBL1200354	Small molecule	Approval	ATC	5	4	4	Drugs and targets
CALCIUM DOBESILATE	CHEMBL2106191	Small molecule	Approval	ATC	2	0	0	Drugs and targets
DEXTROSE	CHEMBL1222250	Small molecule	Approval	ATC	1	0	0	Drugs and targets
HEPARIN	CHEMBL4650299	Oligosaccharide	Approval	ATC	1	0	0	Drugs and targets
LYAPOLATE SODIUM	CHEMBL3559670		Approval	ATC	1	0	0	Drugs and targets
MONOETHANOLAMINE	CHEMBL104943	Small molecule	Approval	ATC	1	0	0	Drugs and targets
PENTOSAN POLYSULFATE SODIUM	CHEMBL1201516	Small molecule	Approval	ATC	1	0	0	Drugs and targets
PHENOL	CHEMBL14060	Small molecule	Approval	ATC	1	0	0	Drugs and targets
SUGAR, INVERT	CHEMBL1201647		Approval	ATC	1	0	0	Drugs and targets

1 to 10 of 18

See all 18 drugs

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SCN4A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6329	Drugs and targets
ADRA1A	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/146	Drugs and targets
ADRA2A	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/152	Drugs and targets
ADRB1	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/154	Drugs and targets
ADRB3	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/155	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01072877	Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence	Phase 3	279	2014-05-16	Varicose Veins	POLIDOCANOL	Its record names the disease	ClinicalTrials.gov
NCT01231373	Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence	Phase 3	235	2014-04-02	Varicose Veins	POLIDOCANOL, VEHICLE	Its record names the disease	ClinicalTrials.gov
NCT01197833	Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities	Phase 3	117	2014-09-15	Great Saphenous Vein Incompetence, Visible Varicosities	POLIDOCANOL	Its record names the disease	ClinicalTrials.gov
NCT00758420	Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence	Phase 2/3	77	2014-03-24	Varicose Veins	POLIDOCANOL	Its record names the disease	ClinicalTrials.gov
NCT00442364	Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt	Phase 2	60	2014-02-26	Varicose Veins	POLIDOCANOL	Its record names the disease	ClinicalTrials.gov
NCT02462720	COMFORT: A Multicenter, Open-label, Randomized, Crossover Study	Phase 4	35	2018-01-23	Varicose Veins	POLIDOCANOL	Its record names the disease	ClinicalTrials.gov
NCT01428076	Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)	Phase 1	21	2014-03-31	Varicose Veins	POLIDOCANOL	Its record names the disease	ClinicalTrials.gov
NCT00928421	An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins	Phase 2	16	2014-04-02	Varicose Veins	POLIDOCANOL	Its record names the disease	ClinicalTrials.gov
NCT02557542	Pilot RCT Evaluating a One Stop Vein Clinic	Not applicable	3	2025-05-16	Varicose Veins	POLIDOCANOL, SODIUM TETRADECYL SULFATE	Its record names the disease	ClinicalTrials.gov
NCT05707169	Comparison of Zero- and Two-centimeter Distance From Sapheno-femoral Junction in Laser Ablation of Varicose Vein	Not applicable	800		Varicose Veins, Venous Reflux, Venous Insufficiency, Venous Leg Ulcer	EPINEPHRINE, LEVOBUPIVACAINE, LIDOCAINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Polidocanol Injectable Foam, 1.0% vs Placebo: serious adverse events	1 of 39	1 of 38	77	NCT00758420	Trial comparisons
Varithena® vs Radiofrequency Ablation: deaths from any cause	0 of 34	0 of 34	68	NCT02462720	Trial comparisons
Varithena® vs Radiofrequency Ablation: serious adverse events	0 of 34	0 of 34	68	NCT02462720	Trial comparisons
Varithena® vs Radiofrequency Ablation: Patient Preference	19 of 33	14 of 33	66	NCT02462720	Trial comparisons
Polidocanol 1% vs Polidocanol 2%: serious adverse events	0 of 9	0 of 12	21	NCT01428076	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27013511	DERIVED	1	PubMed
26992303	DERIVED	1	PubMed
26957489	DERIVED	1	PubMed
26384639	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0002619

GET https://conductscience.org/api/diseases/v1/HP_0002619/drugs

API reference For AI assistants